Your session is about to expire
← Back to Search
CFI-400945 + Azacitidine for Leukemia (TWT-202 Trial)
TWT-202 Trial Summary
This trial will test the safety of CFI-400945, either alone or in combination with azacitidine or decitabine, in people with blood cancer.
TWT-202 Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.TWT-202 Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am older than 18 years.My AML, MDS, or CMML has not improved after treatment with hypomethylating agents.My disease has returned or didn't respond to treatment.I have AML, MDS, or CMML that is either untreated or has not responded to treatment.I haven't had any cancer treatments like chemotherapy or immunotherapy in the last 14 days.I had a stem cell transplant for AML within the last 90 days or am on immunosuppressive therapy for GVHD.I am on immunosuppressive therapy due to severe side effects from a bone marrow transplant.I am fully active or can carry out light work.
- Group 1: 1A: Monotherapy escalation and expansion
- Group 2: 2A: Combination escalation and expansion
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still openings for participation in this experiment?
"Clinicaltrials.gov shows that this medical trial is actively seeking participants, having initially been posted in April 2021 and recently modified on July 2022."
How many participants is the research team currently recruiting for this trial?
"In order to successfully complete the trial, 72 eligible patients must be recruited. This endeavor is being conducted by Treadwell Therapeutics, Inc across multiple sites including University of Alberta located in Edmonton and New york Presbyterian Weill Cornell Medical Center situated in New York City."
How many venues are hosting this trial's proceedings?
"Seven medical centres are conducting this clinical trial, such as The University of Alberta in Edmonton, New york Presbyterian Weill Cornell Medical Center in NYC and the Ohio State University Comprehensive Cancer Centre. There are also four other locations taking part."
What is the desired result of conducting this experiment?
"This three year trial will monitor the efficacy of CFI-400945 in treating Myelodysplastic syndrome, Chronic myelomonocytic leukemia, and Acute myeloid leukaemia. Primary outcomes include changes to clinical laboratory tests while secondary assessments measure overall response rate (ORR), area under curve (AUC) values for pharmacokinetics, and maximum plasma concentrations at Tmax (Cmax)."
To what primary purpose is CFI-400945 typically administered?
"CFI-400945 is a potent drug that can be leveraged for induction chemotherapy. Additionally, it has been tested to treat intermediate-2 ipss risk category cases, refractory anemias and acute myelocytic leukemia."
Could you elaborate on the other investigations involving CFI-400945?
"At this moment, 263 studies are examining the effects of CFI-400945 with 46 trials in their final stage. Most research is conducted at Reggio Emilia and Foggia; however, there are 6546 sites currently running experiments on CFI-400945."
Share this study with friends
Copy Link
Messenger